Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

SKbioland

KOSDAQ:A052260
Snowflake Description

Excellent balance sheet established dividend payer.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
A052260
KOSDAQ
₩347B
Market Cap
  1. Home
  2. KR
  3. Household
Company description

SKbioland Co., Ltd. manufactures and sells raw materials for cosmetics, and food and pharmaceuticals. The last earnings update was 33 days ago. More info.


Add to Portfolio Compare Print
A052260 Share Price and Events
7 Day Returns
10.5%
KOSDAQ:A052260
1.4%
KR Personal Products
1.9%
KR Market
1 Year Returns
29.1%
KOSDAQ:A052260
-24.6%
KR Personal Products
-21.8%
KR Market
A052260 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
SKbioland (A052260) 10.5% -7.2% 4.8% 29.1% 32% -16%
KR Personal Products 1.4% -9.7% -18% -24.6% -25.9% -38.4%
KR Market 1.9% -14.7% -19.6% -21.8% -19.8% -22%
1 Year Return vs Industry and Market
  • A052260 outperformed the Personal Products industry which returned -24.6% over the past year.
  • A052260 outperformed the Market in Korea (Republic of) which returned -21.8% over the past year.
Price Volatility
A052260
Industry
5yr Volatility vs Market

A052260 Value

 Is SKbioland undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of SKbioland to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for SKbioland.

KOSDAQ:A052260 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.3%
Perpetual Growth Rate 10-Year KR Government Bond Rate 3.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for KOSDAQ:A052260
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year KR Govt Bond Rate 3.4%
Equity Risk Premium S&P Global 6.1%
Personal Products Unlevered Beta Simply Wall St/ S&P Global 0.59
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.594 (1 + (1- 30%) (11.61%))
0.76
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 3.43% + (0.8 * 6.07%)
8.29%

Discounted Cash Flow Calculation for KOSDAQ:A052260 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for SKbioland is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

KOSDAQ:A052260 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (KRW, Millions) Source Present Value
Discounted (@ 8.29%)
2020 8,000.00 Analyst x1 7,387.84
2021 9,000.00 Analyst x1 7,675.34
2022 9,774.90 Est @ 8.61% 7,698.31
2023 10,464.61 Est @ 7.06% 7,610.86
2024 11,089.16 Est @ 5.97% 7,447.96
2025 11,666.55 Est @ 5.21% 7,236.16
2026 12,211.81 Est @ 4.67% 6,994.77
2027 12,736.99 Est @ 4.3% 6,737.34
2028 13,251.49 Est @ 4.04% 6,473.12
2029 13,762.54 Est @ 3.86% 6,208.34
Present value of next 10 years cash flows ₩71,470.00
KOSDAQ:A052260 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= ₩13,762.54 × (1 + 3.43%) ÷ (8.29% – 3.43%)
₩293,134.26
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= ₩293,134.26 ÷ (1 + 8.29%)10
₩132,234.10
KOSDAQ:A052260 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= ₩71,470.00 + ₩132,234.10
₩203,704.10
Equity Value per Share
(KRW)
= Total value / Shares Outstanding
= ₩203,704.10 / 15.00
₩13580.27
KOSDAQ:A052260 Discount to Share Price
Calculation Result
Value per share (KRW) From above. ₩13,580.27
Current discount Discount to share price of ₩23,100.00
= -1 x (₩23,100.00 - ₩13,580.27) / ₩13,580.27
-70.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of SKbioland is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for SKbioland's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are SKbioland's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
KOSDAQ:A052260 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in KRW ₩723.26
KOSDAQ:A052260 Share Price ** KOSDAQ (2020-04-03) in KRW ₩23100
Korea (Republic of) Personal Products Industry PE Ratio Median Figure of 24 Publicly-Listed Personal Products Companies 25.33x
Korea (Republic of) Market PE Ratio Median Figure of 1,311 Publicly-Listed Companies 12.31x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of SKbioland.

KOSDAQ:A052260 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= KOSDAQ:A052260 Share Price ÷ EPS (both in KRW)

= 23100 ÷ 723.26

31.94x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • SKbioland is overvalued based on earnings compared to the KR Personal Products industry average.
  • SKbioland is overvalued based on earnings compared to the Korea (Republic of) market.
Price based on expected Growth
Does SKbioland's expected growth come at a high price?
Raw Data
KOSDAQ:A052260 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 31.94x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
9%per year
Korea (Republic of) Personal Products Industry PEG Ratio Median Figure of 12 Publicly-Listed Personal Products Companies 1.21x
Korea (Republic of) Market PEG Ratio Median Figure of 356 Publicly-Listed Companies 0.71x

*Line of best fit is calculated by linear regression .

KOSDAQ:A052260 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 31.94x ÷ 9%

3.55x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • SKbioland is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on SKbioland's assets?
Raw Data
KOSDAQ:A052260 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in KRW ₩10,381.57
KOSDAQ:A052260 Share Price * KOSDAQ (2020-04-03) in KRW ₩23100
Korea (Republic of) Personal Products Industry PB Ratio Median Figure of 40 Publicly-Listed Personal Products Companies 1.52x
Korea (Republic of) Market PB Ratio Median Figure of 1,954 Publicly-Listed Companies 0.84x
KOSDAQ:A052260 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= KOSDAQ:A052260 Share Price ÷ Book Value per Share (both in KRW)

= 23100 ÷ 10,381.57

2.23x

* Primary Listing of SKbioland.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • SKbioland is overvalued based on assets compared to the KR Personal Products industry average.
X
Value checks
We assess SKbioland's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Personal Products industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Personal Products industry average (and greater than 0)? (1 check)
  5. SKbioland has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

A052260 Future Performance

 How is SKbioland expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is SKbioland expected to grow at an attractive rate?
  • SKbioland's earnings growth is expected to exceed the low risk savings rate of 3.4%.
Growth vs Market Checks
  • SKbioland's earnings growth is positive but not above the Korea (Republic of) market average.
  • SKbioland's revenue growth is expected to exceed the Korea (Republic of) market average.
Annual Growth Rates Comparison
Raw Data
KOSDAQ:A052260 Future Growth Rates Data Sources
Data Point Source Value (per year)
KOSDAQ:A052260 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 9%
KOSDAQ:A052260 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 7.3%
Korea (Republic of) Personal Products Industry Earnings Growth Rate Market Cap Weighted Average 18.7%
Korea (Republic of) Personal Products Industry Revenue Growth Rate Market Cap Weighted Average 7.5%
Korea (Republic of) Market Earnings Growth Rate Market Cap Weighted Average 27.8%
Korea (Republic of) Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
KOSDAQ:A052260 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in KRW Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
KOSDAQ:A052260 Future Estimates Data
Date (Data in KRW Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 123,000 17,000 13,000 1
2020-12-31 115,000 17,000 12,000 1
2020-04-04
KOSDAQ:A052260 Past Financials Data
Date (Data in KRW Millions) Revenue Cash Flow Net Income *
2019-12-31 106,311 11,353 10,849
2019-09-30 106,474 14,241 11,908
2019-06-30 107,525 10,948 13,548
2019-03-31 101,903 19,373 16,401
2018-12-31 100,589 15,866 15,047
2018-09-30 101,039 20,604 14,386
2018-06-30 102,362 19,707 14,600
2018-03-31 101,258 14,542 12,002
2017-12-31 102,557 14,013 11,979
2017-09-30 102,174 5,938 12,389
2017-06-30 97,594 8,700 11,540
2017-03-31 101,468 9,042 12,443

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • SKbioland's earnings are expected to grow by 9% yearly, however this is not considered high growth (20% yearly).
  • SKbioland's revenue is expected to grow by 7.3% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
KOSDAQ:A052260 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from SKbioland Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

KOSDAQ:A052260 Future Estimates Data
Date (Data in KRW Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 874.00 874.00 874.00 1.00
2020-12-31 797.00 797.00 797.00 1.00
2020-04-04
KOSDAQ:A052260 Past Financials Data
Date (Data in KRW Millions) EPS *
2019-12-31 723.26
2019-09-30 793.89
2019-06-30 903.25
2019-03-31 1,093.54
2018-12-31 1,003.16
2018-09-30 960.03
2018-06-30 973.99
2018-03-31 801.05
2017-12-31 799.00
2017-09-30 824.95
2017-06-30 769.14
2017-03-31 828.85

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • SKbioland is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess SKbioland's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Korea (Republic of) market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Korea (Republic of) market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
SKbioland has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

A052260 Past Performance

  How has SKbioland performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare SKbioland's growth in the last year to its industry (Personal Products).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • SKbioland's year on year earnings growth rate has been positive over the past 5 years, however the most recent earnings are below average.
  • SKbioland's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • SKbioland's 1-year earnings growth is negative, it can't be compared to the KR Personal Products industry average.
Earnings and Revenue History
SKbioland's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from SKbioland Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

KOSDAQ:A052260 Past Revenue, Cash Flow and Net Income Data
Date (Data in KRW Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 106,310.86 10,848.89 16,593.40 6,313.76
2019-09-30 106,473.77 11,908.42 16,585.08 6,403.84
2019-06-30 107,524.97 13,548.34 15,833.98 6,403.84
2019-03-31 101,902.64 16,401.18 14,828.54 6,197.57
2018-12-31 100,589.35 15,047.41 15,242.47 6,373.64
2018-09-30 101,039.16 14,386.37 14,346.64 6,066.19
2018-06-30 102,362.04 14,600.00 13,877.33 6,066.19
2018-03-31 101,258.29 12,001.81 15,055.65 4,639.94
2017-12-31 102,557.18 11,978.97 13,276.78 6,142.30
2017-09-30 102,174.06 12,388.78 14,046.11 6,285.58
2017-06-30 97,594.22 11,539.63 14,560.39 6,285.58
2017-03-31 101,468.14 12,443.22 13,195.77 7,547.97
2016-12-31 97,808.34 12,426.43 14,910.21 5,736.42
2016-09-30 92,575.31 10,724.38 14,557.61 5,318.00
2016-06-30 90,521.53 11,005.23 12,735.22 6,476.05
2016-03-31 83,825.94 10,528.92 14,003.32 4,577.11
2015-12-31 80,902.06 10,785.47 13,608.42 4,082.66
2015-09-30 80,104.25 10,526.14 14,220.38 3,496.68
2015-06-30 78,481.86 10,980.90 13,319.53 3,090.09
2015-03-31 77,811.28 10,275.44 12,235.49 2,808.95
2014-12-31 76,987.85 10,563.49 12,018.97 2,533.78
2014-09-30 75,369.97 10,611.95 10,294.96 2,811.55
2014-06-30 73,914.60 9,226.68 10,544.45 2,317.87
2014-03-31 72,358.26 9,562.90 10,569.73 2,453.79
2013-12-31 71,029.78 9,727.89 10,093.19 2,661.57
2013-09-30 70,205.30 7,587.02 10,097.18 2,894.21
2013-06-30 69,801.23 8,765.19 9,512.01 3,611.60

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • SKbioland has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • SKbioland used its assets more efficiently than the KR Personal Products industry average last year based on Return on Assets.
  • SKbioland's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess SKbioland's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Personal Products industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
SKbioland has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

A052260 Health

 How is SKbioland's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up SKbioland's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • SKbioland is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • SKbioland's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of SKbioland's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from SKbioland Company Filings, last reported 3 months ago.

KOSDAQ:A052260 Past Debt and Equity Data
Date (Data in KRW Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 155,723.55 39,938.68 14,314.12
2019-09-30 152,800.67 39,964.92 13,964.06
2019-06-30 151,603.28 37,649.19 12,375.88
2019-03-31 149,775.56 33,741.37 22,262.40
2018-12-31 148,905.96 30,451.43 20,545.93
2018-09-30 144,556.22 28,421.29 17,593.30
2018-06-30 142,606.80 27,960.26 19,227.11
2018-03-31 137,720.36 26,482.31 15,201.63
2017-12-31 137,816.15 23,744.15 18,989.10
2017-09-30 135,023.07 21,083.33 17,196.29
2017-06-30 131,721.63 21,208.33 17,143.18
2017-03-31 129,002.76 21,333.33 19,146.08
2016-12-31 130,532.10 21,458.33 25,133.18
2016-09-30 125,929.84 21,583.33 25,579.81
2016-06-30 124,231.25 21,708.33 22,632.41
2016-03-31 121,063.31 17,033.33 22,323.52
2015-12-31 121,815.94 17,158.33 23,985.53
2015-09-30 119,456.62 14,000.00 19,193.66
2015-06-30 116,874.14 16,000.00 16,700.53
2015-03-31 114,071.06 16,000.00 18,227.38
2014-12-31 114,482.62 16,000.00 19,126.85
2014-09-30 112,842.88 21,000.00 26,568.26
2014-06-30 109,718.68 21,000.00 25,161.99
2014-03-31 107,870.68 24,150.00 26,116.43
2013-12-31 107,400.97 24,150.00 27,482.56
2013-09-30 105,142.37 27,000.00 26,242.76
2013-06-30 103,865.06 27,000.00 21,894.70
  • SKbioland's level of debt (25.6%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (14% vs 25.6% today).
  • Debt is well covered by operating cash flow (28.4%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 27.1x coverage).
X
Financial health checks
We assess SKbioland's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. SKbioland has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

A052260 Dividends

 What is SKbioland's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.3%
Current annual income from SKbioland dividends. Estimated to be 1.3% next year.
If you bought ₩2,000 of SKbioland shares you are expected to receive ₩26 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • SKbioland's pays a higher dividend yield than the bottom 25% of dividend payers in Korea (Republic of) (1.25%).
  • SKbioland's dividend is below the markets top 25% of dividend payers in Korea (Republic of) (3.9%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
KOSDAQ:A052260 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Korea (Republic of) Personal Products Industry Average Dividend Yield Market Cap Weighted Average of 18 Stocks 0.8%
Korea (Republic of) Market Average Dividend Yield Market Cap Weighted Average of 908 Stocks 2.9%
Korea (Republic of) Minimum Threshold Dividend Yield 10th Percentile 0.6%
Korea (Republic of) Bottom 25% Dividend Yield 25th Percentile 1.2%
Korea (Republic of) Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

KOSDAQ:A052260 Future Dividends Estimate Data
Date (Data in ₩) Dividend per Share (annual) Avg. No. Analysts
2021-12-31 300.00 1.00
2020-12-31 300.00 1.00
2020-04-04
KOSDAQ:A052260 Past Annualized Dividends Data
Date (Data in ₩) Dividend per share (annual) Avg. Yield (%)
2020-03-02 300.000 1.384
2019-11-14 300.000 1.405
2019-08-14 300.000 2.174
2012-03-28 200.000 1.407
2011-03-15 200.000 1.669
2010-03-30 150.000 1.610
2010-03-29 150.000 2.132
2010-03-26 150.000 2.084

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been stable in the past 10 years.
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of SKbioland's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (2.4x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (2.9x coverage).
X
Income/ dividend checks
We assess SKbioland's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.6%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can SKbioland afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. SKbioland has a total score of 5/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

A052260 Management

 What is the CEO of SKbioland's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Chan-Bok Jeong
AGE 63
TENURE AS CEO 25.3 years
CEO Bio

Mr. Chan-Bok Jeong serves as the Chairman of Bioland Ltd. and has been its Chief Executive Officer since 1995. Mr. Jeong served as Head of Research and Development at Miju Chemical Co. since 1987 until 1989, Sales Director of Lees Corporation since 1989 until 1995. Mr. Jeong graduated from Konkuk University, majored in Microbial Technology; Master’s degree in Food Science and Biotechnology from Kyungnam University in 2005; Doctorate’s degree in Food Science and Biotechnology from Kyungnam University in 2009 and Laboratory in Hankook Cosmetics Co., Ltd. from 1982 to 1987.

CEO Compensation
  • Insufficient data for Chan-Bok to compare compensation growth.
  • Insufficient data for Chan-Bok to establish whether their remuneration is reasonable compared to companies of similar size in .
Management Team

Chan-Bok Jeong

TITLE
Chairman and Chief Executive Officer
AGE
63
TENURE
25.3 yrs

In-Kuk Im

TITLE
Vice President and Director
AGE
59
Board of Directors Tenure

Average tenure and age of the SKbioland board of directors in years:

17.3
Average Tenure
59
Average Age
  • The average tenure for the SKbioland board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Chan-Bok Jeong

TITLE
Chairman and Chief Executive Officer
AGE
63

In-Kuk Im

TITLE
Vice President and Director
AGE
59
TENURE
25.3 yrs

Taek-Seon Lee

TITLE
Director
AGE
70
TENURE
25.3 yrs

Won-Sang Park

TITLE
Director
AGE
55

Shin-Kyu Lee

TITLE
Director
AGE
61
TENURE
17.3 yrs

Ki-Ho Kim

TITLE
Director
AGE
55
TENURE
17.3 yrs

Seong-Ku Lee

TITLE
Director
AGE
59
TENURE
16.3 yrs

Kwang-Sik Jin

TITLE
Director
AGE
53
TENURE
14.3 yrs

Yi-Seob Jang

TITLE
Director
AGE
61
TENURE
12.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (₩) Value (₩)
X
Management checks
We assess SKbioland's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. SKbioland has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

A052260 News

Simply Wall St News

A052260 Company Info

Description

SKbioland Co., Ltd. manufactures and sells raw materials for cosmetics, and food and pharmaceuticals. It offers anti-aging, moisturizing, whitening, skin protection, and other cosmetic ingredients; functional food ingredients and general food raw materials; and active pharmaceutical ingredients. The company also researches and develops medical devices in the fields of surgery, plastic surgery, orthopedics, ophthalmology, and dentistry. The company was formerly known as Bioland Co., Ltd and changed its name to SKbioland Co., Ltd. in July 2016. SKbioland Co., Ltd. was founded in 1995 and is based in Cheonan, South Korea.

Details
Name: SKbioland Co., Ltd.
A052260
Exchange: KOSDAQ
Founded: 1995
₩346,500,000,000
15,000,000
Website: http://www.biolandkorea.com
Address: SKbioland Co., Ltd.
59, Songjeongri 2-gil,
Byeongcheon,
Cheonan,
Chungcheongnam-do, South Korea
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
KOSDAQ A052260 Common Stock KOSDAQ KR KRW 17. May 2001
Number of employees
Current staff
Staff numbers
0
SKbioland employees.
Industry
Personal Products
Household
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/04 16:12
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/02/06
Last earnings filing: 2020/03/02
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.